TEVA Stock Overview
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Teva Pharmaceutical Industries Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.85 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 0.88 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 33 Year Change | 0% |
| 5 Year Change | -21.50% |
| Change since IPO | -85.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| TEVA | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | 0% | -2.3% | -1.0% |
| 1Y | 0% | 12.4% | 10.1% |
Return vs Industry: TEVA underperformed the Swiss Pharmaceuticals industry which returned 14.3% over the past year.
Return vs Market: TEVA underperformed the Swiss Market which returned 10.6% over the past year.
Price Volatility
| TEVA volatility | |
|---|---|
| TEVA Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 3.1% |
| Market Average Movement | 3.2% |
| 10% most volatile stocks in CH Market | 7.0% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: TEVA's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: Insufficient data to determine TEVA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1901 | 35,737 | Richard Francis | www.tevapharm.com |
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas.
Teva Pharmaceutical Industries Limited Fundamentals Summary
| TEVA fundamental statistics | |
|---|---|
| Market cap | CHF 18.63b |
| Earnings (TTM) | -CHF 396.90m |
| Revenue (TTM) | CHF 14.27b |
1.3x
P/S Ratio-46.9x
P/E RatioIs TEVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TEVA income statement (TTM) | |
|---|---|
| Revenue | US$16.29b |
| Cost of Revenue | US$8.23b |
| Gross Profit | US$8.06b |
| Other Expenses | US$8.52b |
| Earnings | -US$453.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 49.50% |
| Net Profit Margin | -2.78% |
| Debt/Equity Ratio | 284.0% |
How did TEVA perform over the long term?
See historical performance and comparison